[Skip to Content]
[Skip to Content Landing]
Article
May 1927

BISMUTH THIOGLYCOLLATE IN EXPERIMENTAL AND CLINICAL TREATMENT OF SYPHILIS

Author Affiliations

DETROIT

From From the Research Laboratories of Parke, Davis and Company, and the Detroit Dermatologic Clinic.

Arch Derm Syphilol. 1927;15(5):550-567. doi:10.1001/archderm.1927.02370290025002
Abstract

With the advent of bismuth therapy in syphilis it has become evident that the insoluble and soluble bismuth preparations suspended in organic oils are absorbed slowly,1 because they are insoluble to begin with, or are rendered insoluble because of the unstable chemical nature.2

Besides having a slow rate of absorption, some of the present bismuth preparations produce lumps and cause pain, and occasionally death may result from oil embolism after an accidental injection into the blood stream.3

The present water soluble bismuth preparations either are too toxic or produce too severe an injury at the site of injection to be of practical value in the treatment of syphilis.4

With this in view it was necessary to search for a bismuth preparation which would be free from the foregoing undesirable features.

In a series of soluble bismuth compounds prepared by one of us (Lyons), a bismuth derivative

×